confirmbiosciences.com

— Confirm BioSciences, a leading provider of comprehensive screening tools and solutions, announced today that the company has been acquired by Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U. S. Confirm will continue to operate as a subsidiary under its current name. The acquisition expands Confirm’s access to lab testing services and R&D capabilities, while CRL leverages Confirm’s massive customer base in Drugs of Abuse testing, large consumer-based retail contracts and current pipeline of COVID-19 testing products. CRL, which is CAP, CLIA and SAMHSA certified, performs high complexity molecular diagnostic tests including COVID-19 testing, toxicology and general lab testing, working with a diverse array of partners. The company’s product portfolio ranges from instant and lab-based testing solutions for drugs of abuse, including HairConfirm® and DrugConfirm®, to HealthConfirm®, a line of testing solutions for health and wellness, with results delivered in insightful user-friendly reports.

A third-party audit and certification by UL, a global safety science leader, recognized that Confirm BioSciences meets quality management system requirements to provide medical devices and related services, consistently meeting customer and regulatory requirements according to standards published by the International Organization for Standardization (ISO). Quality is a top priority in everything we do, which is how we’ve been able to grow our Drugs of Abuse testing line so rapidly while adding important new products that support Health & Wellness and COVID-19 testing efforts, including highly accurate antibody and antigen tests and testing controls. UL, which conducted the third-party audit of Confirm BioSciences and issued the ISO 13485:2016 certification, is authorized to certify that companies meet the standards published by ISO, an independent, non-governmental global organization with 165 members representing national standards bodies worldwide. The company’s product portfolio ranges from instant and lab-based testing solutions for drugs of abuse, including HairConfirm® and DrugConfirm®, to HealthConfirm®, a line of testing solutions for health and wellness, with results delivered in insightful user-friendly reports.

— Confirm BioSciences, a leading provider of comprehensive screening tools and solutions, today announced that its recent pilot program with Mission Healthcare demonstrates that a data-centric corporate wellness program can help companies address workforce-specific health and wellness pain points. In their ongoing pilot program with HealthState, Mission Healthcare has achieved a 36% participation rate, which exceeds the industry average by 80%, despite the fact that the majority of Mission Healthcare’s staff works remotely1. Mission Healthcare partnered with Confirm BioSciences to implement wellness benefits via the HealthState platform, including two at-home health and hormone testing kits — tests traditionally seen administered at a doctor’s office — to provide personalized and detailed health reports. The company’s product portfolio ranges from instant and lab-based testing solutions for drugs of abuse, including HairConfirm® and DrugConfirm®, to HealthConfirm® and HealthState®, a line of testing solutions for health and wellness, with results delivered in insightful user-friendly reports.

Impressive sensitivity and specificity results demonstrate that the serology test offered by Confirm Biosciences can serve as a leading screening tool for COVID-19 infection SAN DIEGO, June 11, 2020 /PRNewswire/ — Confirm BioSciences, a leading provider of comprehensive screening tools and solutions, today announced that a COVID-19 antibody test the company offers, manufactured by Healgen Scientific, performed exceptionally well in a recent serological test validation project conducted by National Institutes of Health (NIH) Using the reverse transcription polymerase chain reaction (RT-PCR) lab technique as well as CDC Lab Developed ELISA to determine sensitivity and specificity, researchers rated Healgen at 97% sensitivity and 98% specificity with IgG and at 100% sensitivity and 100% specificity with IgM. A case study with more details is available at the Confirm BioSciences site at https://www.confirmbiosciences.com/covid-19-resources/nci-confirm-biosciences-covid-19-test-validation/. Confirm BioSciences is a leading provider of high-quality, comprehensive screening tools and solutions across the full spectrum of health and wellness.